keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H3B-5942 是不可逆的、选择性的、可口服的雌激素受体共价拮抗剂,能够靶作用于 Cys530,使野生型和突变型ERα失活,能够抑制 ERα 的目标基因GREB1的表达。它具有抗癌活性,对含有 ERαWT 或者突变型 ERα 的肿瘤细胞和动物具有抗肿瘤作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 523 | 现货 | ||
2 mg | ¥ 789 | 现货 | ||
5 mg | ¥ 1,580 | 现货 | ||
10 mg | ¥ 2,380 | 现货 | ||
25 mg | ¥ 3,980 | 现货 | ||
50 mg | ¥ 5,680 | 现货 | ||
100 mg | ¥ 7,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,720 | 现货 |
产品描述 | H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA). |
靶点活性 | Erα (Y537S):0.41 nM (Ki), Erα (WT):1 nM (Ki) |
体外活性 | H3B-5942 dosed once (q.d.×1) orally at 30 to 300 mg/kg showed a dose-proportional increase in plasma and tumor exposure and a concomitant dose-proportional decrease in expression of the ERα target genes PGR and NPY1R in the ERαY537S/WT ST941 tumor model.?Single or repeat dosing of H3B-5942 at 200 mg/kg suppressed a large panel of direct ERα target genes, with q.d.×1 dosing maintaining target gene suppression for up to 72 hours after dose, and q.d.×3 (3 daily doses) dosing demonstrating greatest suppression in PGR and NPY1R |
体内活性 | Single or repeat dosing of H3B-5942 at 200 mg/kg suppressed a large panel of direct ERα target genes, with q.d.×1 dosing maintaining target gene suppression for up to 72 hours after dose, and q.d.×3 (3 daily doses) dosing demonstrating greatest suppression in PGR and NPY1R . |
激酶实验 | ERαWT (297–554) and mutant (297–554) proteins were incubated in 50 mmol/L Tris pH 8.0, 150 mmol/L NaCl, 5% glycerol, and 1 mmol/L TCEP with a 2-fold excess of compound (2 μmol/L H3B-5942:1 μmol/L ERα protein solution) at 4°C overnight.?Mass analyses were carried out (ESI source, 4.0 kV ionization voltage, 250°C capillary temperature, 10 arb sheath gas, S-lens RF level 65) coupled with an Accela Open AS 1250.?Samples (10 μL) were desalted on a C4 column ( 2.1 × 150 mm, 2.6 μm) with a gradient from 5% to 95% B over 10 minutes.?Eluent A consisted of 0.1% formic acid in water, and eluent B consisted of 0.1% formic acid in acetonitrile.?The flow was set to 400 nL/minute.?All solvents were LC/MS grade .?The mass spectrometer was run in positive mode collecting full scan at R = 70,000 from m/z 500 to m/z 2,000.?Data were collected with the Xcalibur 3.1 software. |
动物实验 | Animals were selected based on TV and randomized into treatment groups of 6 to 8 animals per group.?Single-agent or combination treatments were started on day 0 and continued for the duration of the study.?H3B-5942 was administered orally, tamoxifen was given Q2D, fulvestrant was given?, and palbociclib was administered orally ?Each treatment was administered based on BW (10 mL/kg).?H3B-5942 was formulated daily in 10% 2-Hydroxypropyl-β-CycloDextrin (HPβCD) in 5% dextrose, tamoxifen was formulated in 95% peanut oil/5% ethanol (EtOH), clinical-grade fulvestrant was administered, and palbociclib was formulated in 25 mmol/L sodium bicarbonate, 15 mmol/L lactic acid solution with 2% Cremophor EL.?The BW measurements were performed daily, and tumor measurements were recorded twice a week. |
分子量 | 494.63 |
分子式 | C31H34N4O2 |
CAS No. | 2052128-15-9 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (101.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0217 mL | 10.1086 mL | 20.2171 mL | 50.5428 mL |
5 mM | 0.4043 mL | 2.0217 mL | 4.0434 mL | 10.1086 mL | |
10 mM | 0.2022 mL | 1.0109 mL | 2.0217 mL | 5.0543 mL | |
20 mM | 0.1011 mL | 0.5054 mL | 1.0109 mL | 2.5271 mL | |
50 mM | 0.0404 mL | 0.2022 mL | 0.4043 mL | 1.0109 mL | |
100 mM | 0.0202 mL | 0.1011 mL | 0.2022 mL | 0.5054 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
H3B-5942 2052128-15-9 Endocrinology/Hormones Estrogen Receptor/ERR Estrogen/progestogen Receptor Inhibitor H3B5942 H3B 5942 H-3B-5942 inhibit inhibitor